ATTU:NSD-Attunity Ltd (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 23.42

Change

0.00 (0.00)%

Market Cap

USD 0.51B

Volume

179.00

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Attunity Ltd (ATTU) Stock Analysis:
Based on the Attunity Ltd stock forecasts from 0 analysts, the average analyst target price for Attunity Ltd is not available over the next 12 months. Attunity Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Attunity Ltd is Very Bullish, which is based on 1 positive signals and 0 negative signals. At the last closing, Attunity Ltd’s stock price was USD 23.42. Attunity Ltd’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Attunity Ltd
No recent average analyst rating found for Attunity Ltd

About

Attunity Ltd. develops, markets, sells, and supports data integration and Big Data management software solutions worldwide. It offers Attunity Replicate, a data replication software for delivering, sharing, and ensuring the availability of data for meeting business operations, an ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

USD61,525,874.67B 1.10 5.30
FTD FTD Companies, Inc

N/A

USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

N/A

USD24,651,104.38B 166.80 24.48
SNHY Helios Technologies, Inc

N/A

USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

USD8,997,243.52B 175.07 79.98
INSY INSYS Therapeutics, Inc

N/A

USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

USD38,513.36B N/A N/A

ETFs Containing ATTU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)
Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 221.26% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 221.26% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 48.30% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.30% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 74.91% N/A N/A N/A N/A
Risk Adjusted Return 64.48% N/A N/A N/A N/A
Market Capitalization 0.51B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)
Ratio vs. Market
(NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 86.74 N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 54.20 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 8.99% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.89 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike